BLUE ASH, Ohio, Feb. 7, 2024 /PRNewswire/ -- Aprecia, the global leader in 3DP technology for commercial-scale pharmaceutical manufacturing, today announced Andrew Karazim will lead Aprecia's Commercialization efforts as the Chief Commercial Officer. Karazim has more than 25 years of pharmaceutical and biotechnology experience with expertise across sales, marketing and market access.
CINCINNATI, Nov. 15, 2023 /PRNewswire/ -- Aprecia, a precision drug delivery company, has partnered with the research and development experts at Battelle to develop groundbreaking 3D printing platforms with the potential to transform the way medicines are developed, manufactured, distributed, and administered. The advantage of 3D printing technology has revolutionized various industries, and now 3D printing is poised to disrupt the pharmaceutical manufacturing sector.
Aprecia Pharmaceuticals has named Owen Murray as its new CEO. Murray will lead the expansion of Aprecia's offerings in proprietary 3D-printed (3DP) pharmaceutical technologies.
BLUE ASH, Ohio, Jan. 30, 2023 /PRNewswire/ -- Aprecia Pharmaceuticals today announced Owen Murray as its Chief Executive Officer. Murray will lead the expansion of Aprecia's offerings in proprietary 3D-Printed pharmaceutical technologies.
Aprecia Pharmaceuticals announced today that it has chosen Mike Gosselin, Ph.D., as Vice President of Pharmaceutical Development. Gosselin will...
Kyle Smith has been named President and Chief Operating Officer of Aprecia Pharmaceuticals, LLC, responsible for leading day-to-day business activities. Mr. Smith is a 10-year veteran with Aprecia and has served as Vice President of Operations for the past three years.
CINCINNATI, Oct. 21, 2021 /PRNewswire/ -- Kyle Smith has been named President and Chief Operating Officer of Aprecia Pharmaceuticals, LLC, effective immediately. Mr. Smith is a 10-year veteran with Aprecia and has served as Vice President of Operations for the past 3 years. As President and Chief Operating Officer, Mr. Smith will be responsible for leading day-to-day business activities.
Nanoform Finland Plc, a nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, have partnered to explore synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms. This collaboration aims to provide the pharmaceutical industry with new capabilities in patient centric therapies.
Nanoform Finland and Aprecia announced in an April 21, 2021 press release that they are investigating potential synergies between their technologies, with the goal of providing new capabilities for patient-centric therapies in oral and buccal drug-delivery. The companies are combining Nanoform’s fast dissolution, nanoformed particles with Aprecia’s ZipDose three-dimensional printing (3DP) technology platform, which allows rapid disintegration. These features can enable rapid absorption, as well as lower dosage products, less excipient content, and reduced pill burden.
HELSINKI, April 21, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, announce that they are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms. This collaboration seeks to provide customers and the pharmaceutical industry with new capabilities in patient centric therapies.